Professor MOK, Li Shu Fan Professor of Clinical Oncology of CUHK Medicine, presented the study findings at the 54th ASCO annual meeting in June 2018

Abstract

A CUHK-led global study demonstrated that a second-generation targeted therapy resulted in a more than 7-months improvement in the overall survival of advanced non-small-cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) mutation, compared with those treated with conventional first-line treatments. More than half these patients survived 30 months or more.

This Phase 3 clinical trial established that the new treatment is superior to current options and should be considered a standard treatment option for these patients. The results were published in the Journal of Clinical Oncology and presented to oncologists worldwide at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Details: http://bit.ly/2VuGkFZ